Trial · NCT03748823
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomized Treatment Period | STARTED | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 46 | |
| Randomized Treatment Period | STARTED | Ravulizumab SC/SC Treatment Group | 90 | |
| Randomized Treatment Period | Received at Least 1 Dose of Study Drug | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 46 | |
| Randomized Treatment Period | Received at Least 1 Dose of Study Drug | Ravulizumab SC/SC Treatment Group | 90 | |
| Randomized Treatment Period | Treated and Not Included in Analysis | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 1 | |
| Randomized Treatment Period | Treated and Not Included in Analysis | Ravulizumab SC/SC Treatment Group | 6 | |
| Randomized Treatment Period | Full Analysis Set | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 45 | |
| Randomized Treatment Period | Full Analysis Set | Ravulizumab SC/SC Treatment Group | 84 | |
| Randomized Treatment Period | Safety Analysis Set | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 45 | |
| Randomized Treatment Period | Safety Analysis Set | Ravulizumab SC/SC Treatment Group | 84 | |
| Randomized Treatment Period | COMPLETED | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 44 | |
| Randomized Treatment Period | COMPLETED | Ravulizumab SC/SC Treatment Group | 84 | |
| Randomized Treatment Period | NOT COMPLETED | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 2 | |
| Randomized Treatment Period | NOT COMPLETED | Ravulizumab SC/SC Treatment Group | 6 | |
| Extension Period | STARTED | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 44 | |
| Extension Period | STARTED | Ravulizumab SC/SC Treatment Group | 83 | |
| Extension Period | Received at Least 1 Dose of Study Drug | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 44 | |
| Extension Period | Received at Least 1 Dose of Study Drug | Ravulizumab SC/SC Treatment Group | 83 | |
| Extension Period | Treated But Not Included in the Analysis | Ravulizumab Intravenous (IV)/Subcutaneous (SC) Treatment Group | 1 | |
| Extension Period | Treated But Not Included in the Analysis | Ravulizumab SC/SC Treatment Group | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03748823/flow